(Q36174470)

12 August 2017

1 reference

title

Antiinflammatory therapies for cystic fibrosis: past, present, and future (English)

1 reference

12 August 2017

0 references

William A Prescott

1

1 reference

12 August 2017

Cary E Johnson

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

25

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

555-573

1 reference

Inflammation and cystic fibrosis pulmonary disease

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

An overview of the pathogenesis of cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Advanced cystic fibrosis lung disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Inhaled corticosteroids: past lessons and future issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effect of high-dose ibuprofen in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Action of nonsteroidal, anti-inflammatory drugs on human and rat peripheral leucocyte migration in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effects of ibuprofen on endotoxin-induced alveolitis: biphasic dose response and dissociation between inflammation and hypoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Population pharmacokinetics of high dose ibuprofen in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pharmacokinetics of ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Diffuse panbronchiolitis and cystic fibrosis: East meets West

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Erythromycin and diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Therapy with macrolides in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Azithromycin, the multidrug-resistant protein, and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Macrolide drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

The mechanism of action of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Montelukast sodium in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Anti-inflammatory effects of montelukast in mild cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Montelukast pharmacokinetics in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

RETRACTED: Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pentoxifylline reduces injury to isolated lungs perfused with human neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Inhibitory effects of pentoxifylline on LPS-induced leukocyte adhesion and macromolecular extravasation in the microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Essential fatty acid deficiency in well nourished young cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Fatty acids in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.555.61025

10.1592/PHCO.25.4.555.61025

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference